TRACKER 6 OCT 2026 · WADA publishes the 2027 Prohibited List, in force January 1, 2027. What changed
plainly graded.

KPV

Also called "lysine-proline-valine", "alpha-MSH fragment"
FDA: not approved503A compounding: under reviewWADA: not named, ask USADA
STATUS AS OF
FDA: not FDA-approved for any use · 503A: not on the 503A bulks list. FDA advisers recommended it on July 23, 2026; the vote is non-binding and no rule has been proposed · WADA: not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use · tracker entry

The short answer: KPV is a three-amino-acid fragment (lysine-proline-valine) of the hormone alpha-MSH. As of October 17, 2026 it is not FDA-approved, and we found no published human trial of KPV for any condition; the evidence is from mouse studies and gut cells grown in a lab.

Written by Maren Holt 7 PUBLIC SOURCES · UPDATED 17 OCT 2026 · NO TIES TO SELLERS
How we source

We collect and compare information from public, cited sources. We cannot guarantee that it is complete, current or correct. This is not medical advice. Only a doctor can prescribe, and a doctor should confirm anything you read here before you act on it.

Based on public sources; we cannot guarantee it is correct. Not medical advice. A doctor should prescribe and confirm. Full disclaimer

What is KPV?

KPV is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body makes. The peptide sold online is made in a lab.

What is KPV claimed to do, and what does the evidence show?

Overall grade Evidence grade D
Strongest evidenceAnimal and cell studies
GRADE D: ANIMAL OR CELL STUDIES ONLY · HOW WE GRADE
UseClaimedShownGrade
Gut inflammation Calms gut inflammation and colitis Reduced signs of colitis in mice and calmed inflammatory signalling in human gut cells in the lab. No human trial.[4] Evidence grade D
Gut inflammation Evidence grade D
Claimed: Calms gut inflammation and colitis Shown: Reduced signs of colitis in mice and calmed inflammatory signalling in human gut cells in the lab. No human trial.[4]

What are the known risks and side effects of KPV?

An unapproved product has no required quality testing. In July 2026 FDA staff told the agency's advisers they had concerns about impurities, bacterial toxins and unreliable certificates for several of these peptides, and that nobody knows how often they trigger an immune response.

Who should be especially careful
  • People who are pregnant, trying to get pregnant or breastfeeding. There is no human data in pregnancy.
  • Anyone under 18. It has not been studied in young people.
  • Tested athletes and service members. Check with USADA or your service's rules first. A positive test counts whatever the label said.
  • People taking prescription medicines. Interactions have not been studied. Bring the product label to your clinician.
Get medical help now if you have
  • Swelling of the face, lips or throat, trouble breathing, chest pain, a racing heart or fainting. Call 911.
  • Redness spreading from an injection site, warmth, pus or a fever. Get same-day care.
  • Unsure what you took or whether a reaction is serious: Poison Control 1-800-222-1222 (free, 24 hours).
  • Thoughts of harming yourself: call or text 988.

Is KPV banned in sport?

Not named on the 2026 WADA List. Because it is unapproved, the catch-all S0 section may still apply; ask USADA before use.[3] Anti-doping rules work on strict liability: a positive test counts whatever the label said.

What don't we know about KPV?

Still unknown
  • Any effect in people: no human trial has been published.
  • What is actually in products sold online.
  • Effects in pregnancy: there is no human data.
Why this page has no dosing We don't publish doses, schedules or mixing instructions for KPV or any unapproved peptide. No human dose has been established for most of these uses, so we list what to ask a licensed prescriber instead. Here's why, and who can legally answer

What should you tell your doctor if you're using KPV?

Tell them exactly what you took, for how long, and where it came from, and bring the label. These questions can help the conversation:

  • Is there an approved treatment for my goal that has been tested in people?
  • What should I watch for, and which symptoms mean I should stop and call you?
  • Could it interact with the medicines I already take?

Compare next

KLOW, explained
Sources
  1. US Food and Drug Administration. 503A bulk drug substances: interim categories, updated April 15, 2026 , 2026-04-15.
  2. US Food and Drug Administration. Pharmacy Compounding Advisory Committee, meeting of July 23-24, 2026: briefing documents and vote record , 2026-07-23.
  3. World Anti-Doping Agency. 2026 Prohibited List (sections S0 and S2) , 2026-01-01.
  4. Inflammatory Bowel Diseases. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease , 2008. PMID 18092346.
  5. Frier Levitt. FDA peptides 'do not compound' list update 2026 , 2026-04-16. (law-firm or secondary summary)
  6. DLA Piper. FDA AdComm recommends adding six peptides to bulk list , 2026-07-31. (law-firm or secondary summary)
  7. McDermott Will & Emery. Bulk list bound? PCAC backs majority of peptides in two-day public meeting , 2026-07-27. (law-firm or secondary summary)
Changelog
17 OCT 2026 Draft. Statuses read from the regulatory record dated 2026-10-17.
Spotted an error? Report it. We never change a page's updated date without changing its content.